Supernus Pharmaceuticals, Inc. (SUPN) Cash Flow Statement

The wide gap between net income and operating cash flow in 2026Q2 is largely attributable to $25.7M in depreciation and amortization and $8.6M in stock-based compensation, which are non-cash charges. However, the negative working capital change of -$2.8M suggests that cash collections are not keeping pace with accrual-based revenue recognition. Investors should monitor whether the company can sustain positive operating cash flow as it scales, given the recurring pattern of negative net income in recent quarters.

The trajectory of free cash flow is highly erratic, with positive quarters in 2025Q1, 2025Q2, and 2026Q1, but negative in 2025Q3 and 2026Q2. This volatility appears tied to the timing of working capital changes, particularly the $51.4M outflow in 2025Q4 and the $21.8M inflow in 2026Q1. While revenue growth is accelerating, the company's ability to convert that growth into consistent free cash flow remains unproven, and the negative FCF margin of -2.5% in 2026Q2 suggests that operating leverage is not yet translating to cash generation.

Supernus's capital intensity is exceptionally low, with CapEx never exceeding 0.6% of revenue in any quarter. This suggests that the company's growth is not dependent on heavy physical asset investment, but rather on intangible assets such as R&D and acquisitions. The low CapEx also means that depreciation and amortization charges, which totaled $25.7M in 2026Q2, are likely driven by acquired intangibles rather than property, plant, and equipment. This may indicate that the company's cash flow is more sensitive to working capital and operating expenses than to capital investment.

The volatility in working capital is a primary driver of Supernus's erratic operating cash flow. The large outflow in 2025Q4 may reflect inventory build-up or delayed collections, while the inflow in 2026Q1 suggests a reversal. In 2026Q2, a modest outflow of -$2.8M contributed to the negative operating cash flow. This pattern suggests that the company's cash conversion cycle is not stable, and management may be using working capital management to smooth earnings, but the underlying cash generation remains inconsistent. Investors should monitor the efficiency of receivables collection and inventory management as revenue scales.

The absence of shareholder returns is notable, especially given the company's positive free cash flow in several quarters. Instead, the company appears to be reinvesting cash into acquisitions, as evidenced by the $293.1M net cash outflow for acquisitions in 2025Q4. This suggests a growth strategy focused on inorganic expansion, which may be dilutive to shareholders if the acquired assets do not generate adequate returns. The lack of dividends or buybacks may also indicate that management believes internal reinvestment offers higher returns, but investors should assess the effectiveness of this capital deployment.

The cumulative operating cash flow of $281M versus net losses of -$28M over the same period highlights a significant divergence between accrual earnings and cash reality. This gap is primarily due to non-cash charges such as depreciation, amortization, and stock-based compensation, which totaled over $200M. However, the negative working capital changes in several quarters suggest that some of this cash generation may be temporary, as the company may be delaying payments or accelerating collections. Investors should be cautious about extrapolating this trend, as the 2026Q2 data shows a deterioration in cash conversion.